在非小细胞肺癌中,使用定量SPECT/CT评估[99mTc]标记的NM-01(一种单域程序性死亡配体1(PD-L1)抗体)的评估者间和评估者内一致性
本研究纳入14例未经治疗的晚期非小细胞肺癌(NSCLC)患者,在基线(n=3)或基线加9周随访(n=11)时行[99mTc]NM-01 SPECT/CT,由三名独立评估者测量SUVmax及恶性病灶-血池比值。结果显示原发肺肿瘤、淋巴结转移、胸部转移和远处转移的评估者间ICC为0.91–1.00,评估者内ICC范围为0.86–1.00,均呈良好或极好一致性。作者认为需要正在进行的和未来更大队列研究进一步验证。
要点
- NSCLC患者[99mTc]NM-01 SPECT/CT定量测量原发灶及转移灶SUVmax的评估者间ICC为0.91–1.00。
- 间隔28天重复勾画,各病灶及比值的评估者内ICC范围为0.86–1.00。
- 作者认为需要正在进行的和未来更大队列研究进一步验证。
核心结论
- 在NSCLC中,使用恶性原发或转移灶的SUVmax及其与健康参考组织的比值对[99mTc]NM-01 SPECT/CT进行定量评估,在本研究中显示良好或极好的评估者间和评估者内一致性。
- 作者认为需要正在进行的和未来更大队列研究进一步验证。
研究设计与样本
- 参与者(n=14)为未经治疗的晚期NSCLC患者,在基线(n=3)或基线加9周随访(n=11)时行[99mTc]NM-01 SPECT/CT。
- 由三名独立评估者使用Siemens xSPECT Broad Quantification软件测量原发肺、淋巴结、胸部转移和远处转移及健康参考组织的[99mTc]NM-01摄取,采用SUVmax和恶性病灶-血池比值。
- 计算组内相关系数(ICC)并绘制Bland-Altman图以确定评估者间和评估者内一致性。
- 临床试验注册号:NCT04436406(注册于2020年6月18日)和NCT04992715(注册于2021年8月5日)。
主要发现
- 原发肺肿瘤(T;n=25)手动自由勾画SUVmax的评估者间ICC为1.00(95%CI 0.99-1.00)。
- 单个淋巴结转移(LN;n=56)的评估者间ICC为0.97(95%CI 0.95-0.98)。
- 胸部转移(ThMet;n=9)的评估者间ICC为0.94(95%CI 0.83-0.99),远处转移(DisMet;n=21)的评估者间ICC为0.91(95%CI 0.83-0.96)。
- 肿瘤-血池(T:BP)、LN:BP、ThMet:BP和DisMet:BP测量的评估者间ICC也显示良好或极好一致性。
- 间隔28天后对T、LN、ThMet、DisMet及其比值进行手动自由勾画评分,所有评估者的评估者内ICC范围为0.86-1.00,显示良好或极好一致性。
局限性
- 作者认为需要正在进行的和未来更大队列研究进一步验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Immune checkpoint inhibitors, including those against programmed cell death protein-1 (PD-1) or its ligand (PD-L1), are routinely used to treat non-small cell lung cancer (NSCLC). PD-L1 is a validated prognostic and predictive immunohistochemical biomarker of anti-PD-1/PD-L1 therapy but displays temporospatial heterogeneity of expression. Non-invasive radiopharmaceutical techniques, including technetium-99m [99mTc]-labelled anti-PD-L1 single-domain antibody (NM-01) SPECT/CT, have the potential to improve the predictive value of PD-L1 assessment. This study aims to determine the inter- and intra-rater agreement of the quantitative measurement of [99mTc]NM-01 SPECT/CT in NSCLC. METHODS: Participants (n = 14) with untreated advanced NSCLC underwent [99mTc]NM-01 SPECT/CT at baseline (n = 3) or at baseline plus 9-week follow-up (n = 11). [99mTc]NM-01 uptake (of primary lung, lymph node, thoracic and distant metastases, and healthy reference tissues) was measured using SUVmax and malignant lesion-to-blood pool ratios with Siemens xSPECT Broad Quantification software by three independent raters. Intraclass correlation coefficients (ICC) were calculated and Bland-Altman plot analysis performed to determine inter- and intra-rater agreement. RESULTS: There was excellent inter-rater agreement of manual freehand SUVmax scores of primary lung tumour (T; n = 25; ICC 1.00; 95% CI 0.99-1.00), individual lymph node metastases (LN; n = 56; ICC 0.97; 95% CI 0.95-0.98), thoracic metastases (ThMet; n = 9; ICC 0.94; 95% CI 0.83-0.99) and distant metastases (DisMet; n = 21; ICC 0.91; 95% CI 0.83-0.96). The inter-rater ICCs of tumour-to-blood pool (T:BP), LN:BP, ThMet:BP and DisMet:BP measures of [99mTc]NM-01 uptake also demonstrated good or excellent agreement. Manual freehand scoring of T, LN, ThMet, DisMet and their ratios using [99mTc]NM-01 SPECT/CT following a 28-day interval was consistent for all raters with good or excellent intra-rater agreement demonstrated (ICCs range 0.86-1.00). CONCLUSION: Quantitative assessment of [99mTc]NM-01 SPECT/CT in NSCLC, using SUVmax of malignant primary or metastatic lesions and their ratios with healthy reference tissues, demonstrated good or excellent inter- and intra-rater agreement in this study. Further validation with ongoing and future larger cohort studies is now warranted. CLINICAL TRIAL REGISTRATION: ClinicalTrials.gov identifier no. NCT04436406 (registered 18th June 2020; available at https://clinicaltrials.gov/ct2/show/NCT04436406 ) and NCT04992715 (registered 5th August 2021; available at https://clinicaltrials.gov/ct2/show/NCT04992715 ).
引用
- Hughes DJ, Chand G, Johnson J, et al. Inter-rater and intra-rater agreement of [99mTc]-labelled NM-01, a single-domain programmed death-ligand 1 (PD-L1) antibody, using quantitative SPECT/CT in non-small cell lung cancer. EJNMMI Res. 2023. PMID: 37256434. doi:10.1186/s13550-023-01002-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。